EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
<p>5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Ki...
Shranjeno v:
Glavni avtor: | |
---|---|
Format: | Knjiga |
Izdano: |
Journal of Surgery and Surgical Research - Peertechz Publications,
2015-12-17.
|
Teme: | |
Online dostop: | Connect to this object online. |
Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Kopija 1 | Prosto |